Humana Pharmacy Solutions receives URAC accreditation
LOUISVILLE, Ky. — Humana’s pharmacy benefit management business has been awarded pharmacy benefit management accreditation from a nonprofit healthcare accrediting organization.
Humana Pharmacy Solutions was awarded full pharmacy benefit management accreditation by URAC. URAC standards require companies to demonstrate their commitment to quality and safety.
"Humana is honored to receive PBM accreditation from URAC," said William Fleming, Humana Pharmacy Solutions VP. "It’s exciting to us to be recognized in our industry for providing outstanding services. The accreditation renewal also underscores the quality of our work with Humana members, customers, clients, payers and healthcare providers by confirming our compliance with national standards for PBM services."
Endo completes Qualitest acquisition
CHADDS FORD, Pa. — Endo Pharmaceuticals has finished its acquisition of Qualitest Pharmaceuticals for $1.2 billion, Endo said Wednesday.
Endo had agreed to buy Qualitest, a privately owned manufacturer of generic drugs, on Dec. 28.
“This acquisition marks another milestone in the transformation of Endo and accelerates our stated strategy of building a diversified healthcare company, better able to respond to the changing economics that drive the U.S. healthcare environment,” Endo president and CEO David Holveck said. “We believe this transaction provides Endo with an enhanced competitive position and critical mass in the generics market, further diversifying our business lines and product offerings and enhancing our portfolio of pain management products.”
Keryx: Zerenex reduces phosphate levels in patients on kidney dialysis
NEW YORK — Drug maker Keryx Biopharmaceuticals got promising results from a late-stage clinical trial of a drug for treating elevated phosphate levels, also known as hyperphosphatemia, in patients on kidney dialysis, the company said Tuesday.
In a phase-3 trial, Zerenex (ferric citrate) significantly reduced phosphate levels in patients with end-stage kidney disease on dialysis.
“Based on the results of this phase 3 study, it appears that the Zerenex efficacy and safety profile is emerging in a way that could make it the phosphate binder of choice for dialysis patients,” study program chairwoman and Vanderbilt University medical professor Julia Lewis said. “We are very excited to have taken this step forward towards bringing Zerenex to the patients who are in need of additional alternatives to the existing phosphate binders.”